Loading...
Market
How many countries will approve Benralizumab for asthma treatment by end of 2025?
2
Resolution / Starting Odds
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Official approval records from respective countries' health agencies
Story
First New Asthma Treatment in 50 Years: Benralizumab Cuts Attacks by 30% in "Game-Changer" Trial
Nov 28, 2024, 07:56 AM
Researchers have developed the first new treatment for asthma attacks in 50 years, offering hope to millions of sufferers. The injectable drug, benralizumab, developed by AstraZeneca, was found to be more effective than steroid tablets in treating acute attacks of asthma and chronic obstructive pulmonary disease (COPD), reducing the need for further treatment by 30%. The monoclonal antibody targets the interleukin-5 receptor-alpha (IL-5Rα) to suppress part of the immune system and prevent attacks. The clinical trial, conducted by King's College London and published in The Lancet Respiratory Medicine, has been hailed as a "game-changer" by doctors and patients. Approximately 2 million asthma attacks occur annually in the UK, and this breakthrough marks a significant advancement in respiratory medicine.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
United States • 25%
United Kingdom • 25%
European Union • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Top 1 • 25%
Top 2-3 • 25%
Top 4-5 • 25%
Below Top 5 • 25%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%